Robert Langer is the David H. Koch Institute professor at the Massachusetts Institute of Technology. He also runs the Langer Lab and is co-founder of more than 40 biotech companies. His talk with Nature Biotechnology covers the death of his father, his experience teaching high school science and math, and the requirements for launching a successful biotech.

George Church is professor of genetics at Harvard University, and professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology. He is also co-founder of more than 20 biotech companies. His talk with covers being held back in 9 grade, launching the Human Genome Project, and the necessity of surveilling synthetic biologists.

George Church is professor of genetics at Harvard University, and professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology. He is also co-founder of more than 20 biotech companies. His talk with Nature Biotechnology covers being held back in 9th grade, launching the Human Genome Project, and the necessity of surveilling synthetic biologists.

Chad Womack is senior director of STEM initiatives at UNCF. The episode covers Womack's path to HIV research at Harvard, his experience founding a biotech just before the Great Recession, and what the election of President Barack Obama meant to African Americans.

Chad Womack is senior director of STEM initiatives at UNCF. The episode covers Womack's path to HIV research at Harvard, his experience founding a biotech just before the Great Recession, and what the election of President Barack Obama meant to African Americans.

Christoph Lengauer is a venture partner at Third Rock Ventures, the president of Celsius Therapeutics, and executive vice president at Blueprint Medicines. His conversation with Nature Biotechnology covers growing up in Austria, why he nearly gave up research for a career helping settle refugees, and his role in the Henrietta Lacks story.

Christoph Lengauer is a venture partner at Third Rock Ventures, the president of Celsius Therapeutics, and executive vice president at Blueprint Medicines. His conversation with Nature Biotechnology covers growing up in Austria, why he nearly gave up research for a career helping settle refugees, and his role in the Henrietta Lacks story.

Feng Zhang runs the Zhang Lab at the Massachusetts Institute of Technology. He's also a faculty member at the Broad Institute of MIT and Harvard, and has co-founded several biotech companies, including Editas Medicine. His conversation with Nature Biotechnology covers immigrating to America as a boy, his moment of discovery with CRISPR, and what massive success before the age of 35 does to a researcher.

Feng Zhang runs the Zhang Lab at the Massachusetts Institute of Technology. He's also a faculty member at the Broad Institute of MIT and Harvard, and has co-founded several biotech companies, including Editas Medicine. His conversation with Nature Biotechnology covers immigrating to America as a boy, his moment of discovery with CRISPR, and what massive success before the age of 35 does to a researcher.

John Maraganore is CEO of Alnylam Pharmaceuticals. In his talk with he discusses his decade at Biogen, running an RNAi company when skepticism covered the field, and growing up the son of Greek immigrants in Chicago.

John Maraganore is CEO of Alnylam Pharmaceuticals. In his talk with Nature Biotechnology he discusses his decade at Biogen, running an RNAi company when skepticism covered the field, and growing up the son of Greek immigrants in Chicago.

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.

Susan Windham-Bannister is president and CEO of Biomedical Growth Strategies and was the founding president and CEO of the Massachusetts Life Sciences Center (MLSC). Her conversation with Nature Biotechnology covers her childhood in segregated St. Louis, her work at MLSC helping grow the life sciences sector in Massachusetts through Governor Deval Patrick's $1-billion initiative, and race relations in Boston and the United States.

Susan Windham-Bannister is president and CEO of Biomedical Growth Strategies and was the founding president and CEO of the Massachusetts Life Sciences Center (MLSC). Her conversation with Nature Biotechnology covers her childhood in segregated St. Louis, her work at MLSC helping grow the life sciences sector in Massachusetts through Governor Deval Patrick's $1-billion initiative, and race relations in Boston and the United States.

Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.

Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.

Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.

Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.

Jan is the co-founder, CEO and chairman of the Vilcek Foundation, and also a long-time researcher and professor at New York University's School of Medicine. His conversation with Nature Biotechnology covers his harrowing childhood in Czechoslovakia during the rise of Nazi Germany and World War II, his escape from communist Czechoslovakia through defection, and his role in the discovery of the blockbuster drug Remicade.

Jan is the co-founder, CEO and chairman of the Vilcek Foundation, and also a long-time researcher and professor at New York University's School of Medicine. His conversation with Nature Biotechnology covers his harrowing childhood in Czechoslovakia during the rise of Nazi Germany and World War II, his escape from communist Czechoslovakia through defection, and his role in the discovery of the blockbuster drug Remicade.

Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.

Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced.

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced.